24
Participants
Start Date
March 11, 2021
Primary Completion Date
February 8, 2023
Study Completion Date
January 9, 2024
JNJ-73763989
JNJ-73763989 will be administered subcutaneously once every 4 weeks up to Week 44.
JNJ-56136379
JNJ-56136379 tablets will be administered orally once daily up to 48 weeks.
Entecavir (ETV)
ETV tablet will be administered orally once daily up to 48 weeks as NA treatment.
Tenofovir disoproxil
Tenofovir disoproxil will be administered orally once daily up to 48 weeks as NA treatment.
Tenofovir alafenamide (TAF)
TAF will be administered orally once daily up to 48 weeks as NA treatment.
PegIFN-alpha-2a (Optional)
PegIFN-alpha-2a injection will be administered subcutaneously once weekly after Week 40 for either 12 or 24 weeks.
New Zealand Clinical Research, Auckland
UZ Antwerpen, Edegem
Irccs Ospedale Maggiore Di Milano, Milan
Johns Hopkins University, Baltimore
Hopital Beaujon, Clichy
Toronto General Hospital, Toronto
University Medical Center, Hamburg
ID Clinic, Mysłowice
Grahame Hayton Unit, London
Kings College Hospital, London
Janssen Research & Development, LLC
INDUSTRY